Evofem Biosciences, Inc.
EVFM evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for EVFM—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · EVFM
Evofem Biosciences, Inc. is a biopharmaceutical company focused on the development and commercialization of Phexxi, a hormone-free contraceptive vaginal gel, and other multipurpose vaginal pH regulator product candidates.
Key risk: Going concern risk
BioSniper Score
Based on 4 of 6 signals
Financial data as of Jun 30, 2026.
Tracking 3 pipeline candidates for Evofem Biosciences, Inc..
Evofem Biosciences, Inc. is a biopharmaceutical company focused on the development and commercialization of Phexxi, a hormone-free contraceptive vaginal gel, and other multipurpose vaginal pH regulator product candidates.
- As of June 30, 2026, Evofem reported cash & equivalents of $0.3M, total revenue of $2.6M, and a net loss of $11.0M [sec].
- The company has an accumulated deficit of $888.7 million as of December 31, 2023 [sec].
- Phexxi (EVO100) received FDA approval in May 2020 for hormone-free contraception [sec].
- Evofem has incurred significant losses and negative cash flows since inception and expects these to continue for the foreseeable future [sec].
- The company's ability to continue as a going concern is dependent on raising additional capital [sec].
What works
- Phexxi is an FDA-approved, hormone-free contraceptive vaginal gel, providing a differentiated product in the contraceptive market [sec].
- The company has a pipeline of multipurpose vaginal pH regulator (MVP-R) product candidates for potential additional indications [sec].
- Evofem has experience navigating the FDA regulatory process, having successfully obtained approval for Phexxi [sec].
What to weigh
- Evofem has a very limited cash position of $0.3M as of June 30, 2026, and negative shareholders' equity of -$69.6M, indicating severe financial distress [sec].
- The company has an accumulated deficit of $888.7 million as of December 31, 2023, and continues to incur net losses [sec].
- Negative cash flows from operations are expected to continue, and the company's financial condition raises substantial doubt about its ability to continue as a going concern [sec].
- Evofem's ability to fund operations depends on raising additional capital through equity or debt financings, which may not be available on favorable terms [sec].
From the filings
Quoted directly from source documents.
The company has a large accumulated deficit.
“As of December 31, 2023, we had an accumulated deficit of $888.7 million.”
SEC filings · March 27, 2024
Phexxi received FDA approval in May 2020.
“In light of the FDA approval of Phexxi vaginal gel in May 2020”
SEC filings · March 4, 2021
The company expects to continue incurring losses and negative cash flows.
“We have incurred significant losses and negative cash flows since our inception and anticipate we will continue to incur significant losses and negative cash flow for the foreseeable future.”
SEC filings · March 27, 2024
Risks & what to watch (4)›
Key risks
- Going concern risk — Very low cash ($0.3M) and negative equity (-$69.6M) raise substantial doubt about ability to continue operations [sec].
- Dependence on additional financing — Company must raise significant additional funds to finance operations and may not be able to do so [sec].
- History of losses — Accumulated deficit of $888.7M and recurring net losses; profitability not expected in near term [sec].
- Clinical and regulatory risks — Clinical trials are costly and risky; failure to demonstrate safety/efficacy could impair product development [sec].
What to watch
- Ability to raise additional capital through equity or debt financings [sec].
- Commercial performance and revenue generation from Phexxi [sec].
- Progress of clinical development for EVO100 and other pipeline candidates [sec].
- Any changes in the company's going concern status or financial condition [sec].
Sources: SEC filings · Generated August 15, 2026 · How we verify sources →
Run Evofem Biosciences, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Evofem Biosciences, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 4 of 6 signals · derived from public data
1.9 months
OCF -$3M · Net income -$11M
Lead: Approved
3 candidates
No upcoming catalysts tracked
No insider transactions in the last 180 days
Runway
Pipeline
Financials
Institutional Holdings
Source: SEC Form 13F · as of Sep 2023Institutional holders
1
Total value held
$0
| Holder | Shares | Value |
|---|---|---|
| bessemer group inc | 1 | $0 |
Short Interest
as of Apr 6, 2026- % of float
- 11.0%
- Days to cover
- 0.2
- Shares short
- 69,462
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
EVFM short interestGovernance
Frequently asked questions
What is the AI investment thesis for Evofem Biosciences, Inc.?
Evofem Biosciences, Inc. is a biopharmaceutical company focused on the development and commercialization of Phexxi, a hormone-free contraceptive vaginal gel, and other multipurpose vaginal pH regulator product candidates.
What is Evofem Biosciences, Inc.'s lead drug candidate?
Evofem Biosciences, Inc.'s most advanced tracked candidate is phexx (Approved) for prevention of pregnancy.
Who is the CEO of Evofem Biosciences, Inc.?
Ms. Saundra Pelletier is the chief executive officer of Evofem Biosciences, Inc. (EVFM).
Where is Evofem Biosciences, Inc. headquartered?
Evofem Biosciences, Inc. (EVFM) is headquartered in San Diego, CA, United States.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.